✓ Translated by DotMD AI Clinical Council Source: Journal of patient-reported outcomes • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #42329537 ↗

Phase III Randomized Trial: Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library (N = 211)

Original Paper Title: “Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

N = 211

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

The CLL/SLL-related Symptoms, MCL-related Symptoms, and Expanded Fatigue measures showed strong psychometric properties in both CTT and RMT frameworks. Combined with previously published qualitative data, this research showed that the measures are appropriate for use in clinical trials of participants with CLL/SLL and MCL.
Study Design & Sample: Phase III Randomized Trial published in Journal of patient-reported outcomes (N = 211 human participants).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of patient-reported outcomes (2026), this phase iii randomized trial evaluating 211 human participants investigated: Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL): measures of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Symptoms, Mantle Cell Lymphoma (MCL) Symptoms, and an Expanded Fatigue measure. Key clinical takeaway: The CLL/SLL-related Symptoms, MCL-related Symptoms,...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of patient-reported outcomes, 2026-06-22; N = 211; Rigor 82/100): The CLL/SLL-related Symptoms, MCL-related Symptoms, and Expanded Fatigue measures showed strong psychometric properties in both CTT and RMT frameworks. Combined with previously published qualitative data, this research showed that the measures are appropriate for use in clinical trials of participants with CLL/SLL and MCL.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: fatigue → Condition: lymphoma →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42329537: Phase III Randomized Trial: Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library (N = 211)

3 of 3 Free Questions Remaining